Moderna, Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Moderna, Inc. stock analysis MRNA overview
Bullish +65

MRNA Stock Jumps As FDA Backs Flu Shot And Expansion Plans - StocksToTrade

📈 Moderna stock jumped 6.21% on Tuesday, June 23, 2026, rising from a low of $58.70 to close near $63.08 following positive regulatory and corporate news.

✅ The FDA advisory committee voted unanimously (9-0) that the mRNA-1010/mFLUSIVA flu vaccine has a favorable benefit-risk profile for adults aged 50–64 and 65+.

📅 This regulatory vote supports the Biologics License Application ahead of the August 5, 2026 PDUFA deadline for full approval in the U.S.

💰 Moderna reported quarterly revenue of $389M with trailing revenue of $1.94B, though it posted a net loss of $1.34B and EBITDA of -$1.28B.

🛡️ The company holds a strong balance sheet with $5.2B in cash, equivalents, and short-term investments against total liabilities of $4.08B.

🔄 Management announced a restructuring to support three commercial franchises preparing for launches in vaccines, oncology, and rare diseases in 2027–2028.

🇩🇪 Moderna plans to invest in German manufacturing sites, including facilities previously operated by BioNTech, to expand its European footprint.

📉 Analyst Jefferies reiterated a Hold rating with a $45 price target, estimating U.S. flu and combo sales could reach roughly $750M by 2030.

🔬 The upcoming June 25, 2026 Investor Science Day will feature new programs combining mRNA technology with AI and robotics for flu, oncology, and rare disease.

📊 Gross margins stand at 22.6% while EBIT margins are -140%, reflecting heavy R&D and operating spend despite the strengthening stock chart.

Bullish Signals
  • The FDA advisory committee voted unanimously (9-0) to support Moderna's mRNA-1010/mFLUSIVA flu vaccine, significantly reducing regulatory risk for the upcoming PDUFA deadline.
  • Moderna's stock price surged over 34% in less than a month, climbing from $47 to $63, indicating strong investor confidence in the company's strategic pivot.
  • The company possesses a substantial cash cushion of $5.2B against $4.08B in total liabilities, providing ample liquidity to fund restructuring and expansion without immediate distress.
  • Management's announcement of a new three-franchise operating model signals a clear strategic shift away from being a one-hit-wonder post-COVID company.
  • Expansion into German manufacturing sites demonstrates a commitment to building independent global capacity ahead of a broader product wave in vaccines and oncology.
Risk Factors
  • Moderna continues to operate at a significant loss with quarterly net income from continuing operations at -$1.34B and EBITDA of -$1.28B.
  • Gross margins are low at 22.6% and EBIT margins are steeply negative at -140%, reflecting heavy ongoing R&D and operating expenditures that pressure profitability.
  • Free cash flow remains negative at approximately -$692M for the quarter, indicating continued high burn rates despite strong cash reserves.
Full Analysis
Moderna Inc. (NASDAQ: MRNA) shares surged approximately 6.21% on Tuesday, June 23, 2026, driven by a unanimous FDA advisory committee vote favoring its mRNA-1010/mFLUSIVA seasonal flu vaccine for adults aged 50 and older. The stock climbed from roughly $47 to $63 over the preceding month, reflecting strong momentum as investors pivot away from post-COVID concerns toward next-generation flu and oncology franchises. This regulatory milestone supports the company's Biologics License Application ahead of the August 5, 2026 PDUFA deadline. Despite the positive catalysts, Moderna continues to report significant financial losses with quarterly revenue of $389M and a net loss of $1.34B for the quarter. Gross margins remain low at 22.6%, and EBITDA is negative $1.28B, indicating heavy ongoing R&D and operating expenditures. However, the company maintains a robust balance sheet with $5.2B in cash and short-term investments against total liabilities of $4.08B, providing ample liquidity to fund its expansion plans and restructuring efforts. Management announced a strategic restructuring to support three commercial franchises across vaccines, oncology, and rare diseases, aiming for multiple launches between 2027 and 2028. Concurrently, Moderna is expanding its European footprint by investing in German manufacturing sites, including facilities previously operated by BioNTech. Analysts like Jefferies maintain a Hold rating with a $45 price target, noting that meaningful flu revenues are expected to ramp up starting in 2027, potentially reaching $750M in U.S. sales by 2030. The stock's recent performance is attributed to the intersection of regulatory approval signals, corporate restructuring, and aggressive capacity build-out. Upcoming events include Moderna's Investor Science Day on June 25, 2026, where the company plans to showcase new programs leveraging mRNA technology combined with AI and robotics. Traders are closely monitoring these developments as the narrative shifts toward diversification beyond its COVID legacy.